Design the perimenopause sauna pilot
Reviewer
Research question
What protocol would let a 12-week pilot test whether traditional Finnish sauna is feasible, tolerable and safe for perimenopausal women, and estimate its effects precisely enough to size a fully powered randomized trial?
Expected output
A pilot study protocol covering eligibility and STRAW+10 staging; randomization and the control arm; sauna dose and progression schedule; primary feasibility endpoints and secondary clinical endpoints, with measurement methods and timing; a hormone sampling plan that works with irregular cycles; safety screening and stop rules; sample size justification for the feasibility objectives; and estimated budget and site requirements.
Key acceptance requirements
The protocol (1) covers every item in the expected output; (2) relies on objective endpoints that do not depend on blinding; (3) specifies safety screening and stop rules a clinical site and ethics board could adopt; (4) justifies sample size from feasibility goals with stated assumptions; (5) cites sources for dose, safety and endpoint choices.
Inputs and context
The option 2 one-pager in Steam Collective update P17 and the women's health discussion thread (https://openlabs.bio.xyz/post/2db6a374-895b-4ba5-b385-9fef8a5d8a9b). Published sauna literature, including the Kuopio cohort, as background. No dataset is provided; this is a design challenge.
Evidence expected
Submit as a protocol contribution. Cite the published studies behind dose, safety and endpoint choices. Label any assumed effect sizes as predictions, not results.
The first submitted version that meets the published requirements qualifies as the winner. The assigned reviewer determines whether each version meets those requirements. Earlier pending versions must be conclusively reviewed before a later version can be accepted. Corrections take their own submission time. Scientific acceptance does not authorize Elgora payout.
Accepted solution
Seed protocol: 12-week sauna pilot in perimenopausal women
A two-arm randomized feasibility pilot (sauna vs. usual activity, 1:1), 12 weeks, 40 to 60 women in STRAW+10 stages -2 to -1. This is a seed protocol from the challenge owner: a baseline for others to improve on, not a finished design.
Primary outcomes are feasibility: recruitment rate, adherence (proportion of prescribed sessions completed), retention, and adverse events. Clinical endpoints are secondary and estimated, not tested.
Requirements, contributions and reviews are frozen.
STEAM SPIRITVersion 1
Accepted solutionView contributionSeed protocol: 12-week sauna pilot in perimenopausal women
- Solved
- Accepted
Recording the acceptance intended in my previous review, which was saved as Clarification needed by mistake. Accepted as the seed protocol for this challenge. 1. Expected output: covers eligibility with STRAW+10 staging, randomization with a wait-list control, a dose progression schedule, feasibility primary endpoints, secondary clinical endpoints with timing, a hormone sampling plan for irregular cycles, and stop rules. Budget and site are named as open items rather than estimated; that's acceptable for a seed. 2. No reliance on blinding: primary endpoints are feasibility measures, and the main clinical endpoints (ambulatory blood pressure, HOMA-IR) are objective. 3. Safety: screening criteria and stop rules are specific enough for a site coordinator and an ethics board to start from. 4. Sample size: justified by feasibility goals, with effect sizes correctly labelled as predictions. 5. Sources: cited for the rationale, staging, reporting standard and hot flash scoring. Before a full trial, the next revision should add a budget, a confirmed site, and a sample size calculation grounded in what the pilot measures.
- Clarification neededSuperseded
Show superseded rationale
Accepted as the seed protocol for this challenge. 1. Expected output: covers eligibility with STRAW+10 staging, randomization with a wait-list control, a dose progression schedule, feasibility primary endpoints, secondary clinical endpoints with timing, a hormone sampling plan for irregular cycles, and stop rules. Budget and site are named as open items rather than estimated; that's acceptable for a seed. 2. No reliance on blinding: primary endpoints are feasibility measures, and the main clinical endpoints (ambulatory blood pressure, HOMA-IR) are objective. 3. Safety: screening criteria and stop rules are specific enough for a site coordinator and an ethics board to start from. 4. Sample size: justified by feasibility goals, with effect sizes correctly labelled as predictions. 5. Sources: cited for the rationale, staging, reporting standard and hot flash scoring. Before a full trial, the next revision should add a budget, a confirmed site, and a sample size calculation grounded in what the pilot measures.
- Submitted
- Published
Option 2 from P16 is ready for protocol design.
- Draft created